IsoPlexis Co. (NASDAQ:ISO) Sees Significant Growth in Short Interest

IsoPlexis Co. (NASDAQ:ISOGet Rating) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 608,300 shares, an increase of 35.6% from the March 31st total of 448,600 shares. Approximately 4.7% of the company’s shares are short sold. Based on an average daily trading volume, of 90,100 shares, the days-to-cover ratio is presently 6.8 days.

A number of equities analysts recently commented on ISO shares. SVB Leerink reduced their price objective on IsoPlexis from $20.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday, January 27th. Zacks Investment Research downgraded IsoPlexis from a “buy” rating to a “hold” rating in a research report on Wednesday, February 16th. Finally, Morgan Stanley cut their target price on IsoPlexis from $17.00 to $12.00 and set an “overweight” rating for the company in a research note on Tuesday, February 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $14.44.

ISO stock traded up $0.09 during midday trading on Monday, hitting $2.27. 4,630 shares of the company’s stock were exchanged, compared to its average volume of 92,134. The company’s 50-day simple moving average is $3.54. The company has a quick ratio of 9.88, a current ratio of 11.67 and a debt-to-equity ratio of 0.22. IsoPlexis has a 1-year low of $1.62 and a 1-year high of $16.95.

A number of hedge funds have recently bought and sold shares of the business. Citigroup Inc. acquired a new stake in IsoPlexis during the fourth quarter worth $36,000. California State Teachers Retirement System acquired a new stake in shares of IsoPlexis in the fourth quarter valued at $43,000. Deutsche Bank AG acquired a new stake in shares of IsoPlexis in the fourth quarter valued at $47,000. Wells Fargo & Company MN acquired a new stake in shares of IsoPlexis in the fourth quarter valued at $48,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of IsoPlexis in the fourth quarter valued at $51,000. 76.49% of the stock is owned by institutional investors.

IsoPlexis Company Profile (Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea.

Read More

Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.